Drug ID: 3d00000001
Drug Name: C- 1 esterase inhibitor
Generic Names: Cinryze
Category: Hemostatic Agents
Legal Status: Non Opioid Prescription only drug
Indication for Mother: Category C
Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.
Recommended Dose: Adult- The recommended dose is 1000units, for every 3 to 4 days.
Recommended In: This medication is an esterase inhibitor, prescribed for angioedema with hereditary angioedema (HAE). It helps to control inflammation and parts of the immune system.
Directions For Use: It comes as a powder for injection (diluted with fluid) to be administered by a healthcare provider into the vein.
Storage: Store it in refrigerator (2°C–25°C), and protect from light.
Dosage Forms: Reconstituted vials for Intravenous injection
Side Effects: Most Serious Effects - High blood pressure in pregnant women, stroke and blood clot events.
Most Common - Upper respiratory tract infections, inflammation of sinus, rash, and headache.
Miscellaneous - Back pain, pain in extremity and itching.
In Case of Overdose: Thrombotic events have been reported in association with C1 esterase inhibitor products when used off-label at high doses. Animal studies have supported a concern about the risk of thrombosis from intravenous administration of C1 esterase inhibitor products.
Avoid If: Contraindicated in patients with severe life threatening allergic reactions.
Caution should be exercised in patients with history of blood clot events such as deep vein thrombosis and pulmonary embolism, any allergy, who are taking other medications, during pregnancy and breastfeeding.
Rarely patient may develop with increased risk of a viral disease called Creutzfeldt-Jakob disease (brain disease) or a viral disease.
Drug Interaction: No drug interaction studies have been conducted.